Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Public ClinicalTrials.gov record NCT02556372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, pilot study in which JKB-122 is given once daily for 24 weeks in subjects with autoimmune hepatitis (AIH) who have liver enzymes that are 1.25 to 10 times the upper limit of normal (ULN) and who have had a failed response to, incomplete response to, intolerant to, ineligible to, or unwilling to take current immunosuppressant therapies. The dose of JKB-122 will be escalated monthly.
Study identification
- NCT ID
- NCT02556372
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2016
- Primary completion
- Jan 20, 2019
- Completion
- Jan 20, 2019
- Last update posted
- Jul 20, 2020
2016 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ruane Clinical Research Group, Inc. | Los Angeles | California | 90036 | — |
| University of California Davis Medical Center - Ticon 1 | Sacramento | California | 95817 | — |
| California Pacific Medical Center | San Francisco | California | — | — |
| University of Florida Hepatology Research at CTRB | Gainesville | Florida | 32610-0272 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Indiana University School of Medicine | Indianapolis | Indiana | 46202 | — |
| Tulane University | New Orleans | Louisiana | — | — |
| Massachusetts General Hospital | Boston | Massachusetts | — | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Methodist Dallas Medical Center | Dallas | Texas | 75203 | — |
| Advanced Liver Therapies, Baylor College of Medicine | Houston | Texas | 77030 | — |
| The Texas Liver Institute | San Antonio | Texas | 78215 | — |
| Taxes Liver Institute | San Antonio | Texas | — | — |
| Swedish Medical Center - Organ Transplant and Liver Center | Seattle | Washington | 98104 | — |
| University of Washington | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02556372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2020 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02556372 live on ClinicalTrials.gov.